Fig. 5

ECM components contribute to signaling pathways associated with prognosis. A Top 25 up- and downregulated differentially enriched MSigDb hallmark pathways in the ECM-High matreotype compared with the ECM-Low matreotype. Circle size indicates the inverse of the −log10(p-value), color reflects the log fold change (logFC) of the ECM-High matreotype compared with the ECM-Low matreotype. B Pathway analysis of cisplatin-related signatures comparing ECM-High matreotype with the ECM-Low matreotype. C Abundance of CHK2 in the ECM-High matreotype (green) compared with the ECM-Low matreotype (blue). p=1.5E−4, Mann-Whitney U test. D Comparison of the phosphorylated YB1(S102) in the ECM-High matreotype (green) compared with the ECM-Low matreotype (blue). p=1.1E−3, Mann-Whitney U test. E Ligand-receptor interaction results of differentially expressed core matrisomal genes significantly upregulated in ECM-High compared with ECM-Low matreotypes and the receptor groups that they directly interact with. Sector width is the aggregated log fold change of the ligand-receptor interaction strength comparing the ECM-High to ECM-Low matreotype. The scale indicates the width of each link between the ECM category and its cognate receptors. The widths of each link are the maximum fold change of the ligand-receptor interaction scores comparing the ECM-High and ECM-Low groups for that ligand-receptor interaction. F Hallmark pathways regulated by ligand-receptor interactions that are significantly enriched in the ECM-High compared with the ECM-Low matreotypes. The scale indicates the width of each link between the ECM category and the hallmark pathway. The widths of each link are the maximum fold change of the ligand-receptor interaction scores comparing the ECM-High and ECM-Low groups for that hallmark pathway